Last Updated : April 29, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status Sort ascending | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| TBC | risperidone | Schizophrenia, adults | Suspended | |||
| TBC | ruxolitinib | atopic dermatitis | Suspended | |||
| Cosentyx | secukinumab | Hidradenitis suppurativa | Suspended | |||
| Talzenna | talazoparib | Metastatic castration-resistant prostate cancer (mCRPC) | Suspended | |||
| Alsitek | masitinib mesylate | Amyotrophic lateral sclerosis (ALS) | Suspended | |||
| Ikervis | cyclosporine | keratitis, severe | Withdrawn | |||
| Breo Ellipta | fluticasone furoate/vilanterol | COPD | Withdrawn | |||
| TBD | Cabozantinib | Withdrawn | ||||
| Iluvien | fluocinolone acetonide | Diabetic macular edema (DME) | Withdrawn | |||
| Beleodaq | Belinostat | Withdrawn |
Last Updated : April 29, 2024